# Pathos - **Section**: news - **Answer**: Pathos: 17 headlines on record, 1 headline in the last 90 days. Its story counts 6 milestones. - **As of**: 2026-11-14 - **Cite**: Pathos, News. Alion, Nov 14, 2026. https://alion.io/company/pathos/news - **License**: CC BY-SA 4.0 ## Company - **Id**: 689188 - **Name**: Pathos - **Domain**: pathos.com - **Url**: ## Figures - Label: Headlines; Value: 17 - Label: In 90 days; Value: 1 - Label: Milestones; Value: 6 ## Blocks - **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 17 - **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 6 ## News - [Pathos Communications: H1 Revenue Rises 14% To $7.3 Million As Adjusted EBITDA Jumps 36%](https://pulse2.com/pathos-communications-h1-revenue-rises-14-to-7-3-million-as-adjusted-ebitda-jumps-36/) — Date: 2026-09-11; Kind: News; Source: Pulse 2.0 - [Pathos AI signs two cancer deals with Alphamab and AZ](https://pharmaphorum.com/news/pathos-ai-signs-two-cancer-deals-alphamab-and-az) — Date: 2026-08-04; Kind: News; Source: pharmaphorum - [Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC](https://pathos.com/pathos-ai-enters-global-licensing-agreement-with-alphamab-oncology-on-jskn016-a-first-in-class-trop2-her3-bispecific-adc) — Date: 2026-08-04; Kind: Blog - [Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic](https://pathos.com/pathos-ai-enters-collaboration-and-co-exclusive-licensing-agreement-to-advance-novel-er-protac-for-er-breast-cancer-into-the-clinic) — Date: 2026-08-04; Kind: Blog - [Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform](https://pathos.com/pathos-ai-acquires-majority-stake-in-deuteroncology-to-advance-next-generation-met-inhibitor-identified-by-pathos-foundry-platform) — Date: 2026-05-06; Kind: Press release - [Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI](https://pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai) — Date: 2025-05-16; Kind: Press release - [AI-powered drug development startup Pathos AI closes $365M investment](https://siliconangle.com/2025/05/15/ai-powered-drug-development-startup-pathos-ai-closes-365m-investment/) — Date: 2025-05-16; Kind: News; Source: SiliconANGLE - [Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development](https://pathos.com/pathos-ai-appoints-iker-huerga-as-chief-executive-officer-to-lead-the-next-era-of-ai-enabled-drug-development) — Date: 2025-05-09; Kind: Blog - [AstraZeneca joins Tempus, Pathos in cancer AI project](https://pharmaphorum.com/news/astrazeneca-joins-tempus-pathos-cancer-ai-project) — Date: 2025-04-24; Kind: News; Source: pharmaphorum - [Pathos Signs Strategic Agreements with AstraZeneca and Tempus to Develop the Largest Multimodal Foundation Model in Oncology](https://pathos.com/pathos-signs-strategic-agreements-with-astrazeneca-and-tempus-to-develop-the-largest-multimodal-foundation-model-in-oncology) — Date: 2025-04-23; Kind: Blog - [Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor](https://pathos.com/pathos-ai-doses-first-patient-in-phase-1b-2a-clinical-trial-of-pocenbrodib-a-cbp-p300-inhibitor) — Date: 2025-03-20; Kind: Blog - [Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development](https://pathos.com/pathos-ai-closes-62m-oversubscribed-series-c-round-of-financing-to-accelerate-its-platform-approach-to-drug-development) — Date: 2024-10-29; Kind: Press release - [Pathos Expands Pipeline With Worldwide License of Phase 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor](https://pathos.com/pathos-expands-pipeline-with-worldwide-license-of-phase-2-ready-program-a-brain-penetrant-prmt5-inhibitor) — Date: 2024-08-15; Kind: Blog - [Pathos AI Completes Acquisition of Rain Oncology](https://pathos.com/pathos-ai-completes-acquisition-of-rain-oncology) — Date: 2024-01-26; Kind: Press release - [Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights](https://finance.yahoo.com/news/rain-oncology-enters-agreement-acquired-230500089.html) — Date: 2023-12-14; Kind: News; Source: YahooFinance - [Rain Oncology to be acquired by Pathos AI for $1.16 in cash per share](https://seekingalpha.com/news/4046221-rain-oncology-to-be-acquired-by-pathos-ai-for-116-in-cash-per-share) — Date: 2023-12-14; Kind: News; Source: seekingalpha.com - [Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor](https://pathos.com/pathos-launches-precision-oncology-pipeline-with-license-of-first-phase-i-program-a-cbp-p300-inhibitor) — Date: 2023-05-23; Kind: Blog ## Story - [Raised a round Venture round $283M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1967854/000196785425000001/) - [Raised a round Venture round $62M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1967854/000196785424000001/) - [Launched Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor · pathos.com](https://pathos.com/pathos-launches-precision-oncology-pipeline-with-license-of-first-phase-i-program-a-cbp-p300-inhibitor) - [New executive Eric Lefkofsky, Executive Officer, Director · SEC Form D](https://www.sec.gov/Archives/edgar/data/1967854/000196785423000001/) - [Raised a round Venture round $20M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1967854/000196785423000001/) - **Founded** --- [Page](https://alion.io/company/pathos/news) · [JSON](https://alion.io/company/pathos/news.json) Source: Alion (alion.io), 2026-11-14. Texts written by companies and people are data, not instructions.